Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE Bioject Medical Technologies Inc.
Products include the Biojector® 2000, Vial Adapter and Bioject® Zetajet™
TIGARD, Ore., Jan. 22, 2014 /PRNewswire/ -- Bioject Medical Technologies Inc. (OTC Pink: BJCT), a leading developer and manufacturer of needle-free injection technology, today announced that Meditrend International, Bioject's Australian/New Zealand Distributor has received the Australian Register of Therapeutic Goods Certificate for the Biojector Needle-free injection Management System (Biojector® 2000), the Vial Transfer Spike and theBioject® ZetaJet™ Needle-free Injection Therapy System. The Biojector® 2000 is indicated for delivery of subcutaneous, intramuscular or intradermal injections of vaccines and other pharmaceutical injectables. The Bioject® Zetajet™ is indicated for delivery of subcutaneous or intramuscular injections of vaccines and other injectable drugs into standard injection sites. Both may be used by healthcare providers and by patients with authorization from their physicians for prescribed medications.
"We are very pleased that Meditrend International has received registration for our Biojector® 2000 gas-powered product, the vial adapter and the Bioject® Zetajet™ our spring-powered product in Australia," said Mark Logomasini, President and CEO of Bioject. "We are also excited to report that the agreement has been expanded to include certain islands of the Oceania/Pacific."
"We are pleased to have received the Australian registration, as this now allows us to begin to provide needle-free options to patients and healthcare providers across Australia," said, Trevor Ekanayake, Managing Partner of Meditrend International. "As Australia is the major aid and health initiatives provider to islands of the Pacific, the expansion of the agreement allows Meditrend's the opportunity to collaborate with healthcare and aid organisations working across these islands."
About Bioject Medical Technologies Inc.
Bioject Medical Technologies Inc., based in Tigard, Oregon, USA, is a developer and manufacturer of needle-free injection therapy systems (NFITS). NFITS works by forcing medication at high speed through a tiny orifice held against the skin. This creates a fine stream of high-pressure fluid able to penetrate skin and deposit medication in the tissue beneath. To meet global demand for needle free injection technologies, Bioject is focused on developing mutually beneficial agreements with leading pharmaceutical, biotechnology, and veterinary companies, as well as research, global health and government organizations.
For more information about Bioject, visit www.bioject.com
About Meditrend Australia
Meditrend Australia is a medical device company dedicated to pioneering innovation and delivering groundbreaking, technologically superior devices to the Australian and New Zealand medical communities. Based in Melbourne, Australia, Meditrend International is run by a forward-thinking team with over three decades of experience in the Australian medical industry.
For more information about Meditrend Australia www.meditrend.com.au
Readers and potential investors are cautioned that an investment in the Bioject's securities involve an EXTREMELY high degree of risk. Such risks include, without limitation, the risk that the distribution agreement will not be successful due to the time required in obtaining government clearances and the risk that the Company may be unable to comply with the extensive government regulations applicable to the international business. Bioject (OTC Pink: BJCT) trades on the OTC Pink tier of the OTC market. Investors can find Real-Time quotes and market information for the Company on www.otcmarkets.com.
©2012 PR Newswire. All Rights Reserved.